Sign in
Taking people in United StatesPhase 2/3

Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)

Key facts

Who runs it
Vertex Pharmaceuticals Incorporated
Where
Arvada, Boise, Columbus, Edina, El Paso, Gastonia, Greenville, Hinsdale, Houston, Indianapolis, Las Vegas, Lawrenceville, Los Angeles, Miami, Montgomery, New York, Orlando, Roseville, Sacramento, Salt Lake City, San Antonio, Shreveport, Spartanburg, Surprise, Tarzana, Wauwatosa, and Winter Park, United StatesSee the 28 sitesAlso in 13 other countries, 89 sites
Status
Recruiting
Phase
Phase 2/3
People taking part
176 people, planned
Started
30 Sept 2025
Expected to end
29 Dec 2028
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Povetacicept
  • Tacrolimus
Record updated
30 October 2026

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Diagnosed with pMN with confirmatory historical biopsy. If no historical biopsy was performed that confirmed pMN, a biopsy can be performed during Screening to confirm eligibility

Who cannot take part

  • Hypersensitivity to investigational medicinal product or to any of its excipients; Other protocol defined Inclusion/Exclusion criteria will apply

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Where in United States

Also in 13 other countries, 89 sites

  • Western Nephrology & Metabolic Bone Disease, PCArvada, United StatesTaking people
  • CARE Institute - Boise KidneyBoise, United StatesTaking people
  • DaVita Clinical Research ColumbusColumbus, United StatesTaking people
  • DaVita Clinical Research EdinaEdina, United StatesTaking people
  • El Paso Kidney SpecialistsEl Paso, United StatesTaking people
  • Metrolina Nephrology Associates, PAGastonia, United StatesTaking people
  • Carolina Nephrology GreenvilleGreenville, United StatesTaking people
  • NANI ResearchHinsdale, United StatesTaking people
  • DaVita Clinical Research HoustonHouston, United StatesTaking people
  • Provecta Research NetworkHouston, United StatesTaking people
  • Nephrology Associates of Northern Illinois and Indiana (NANI) - Indianapolis SouthIndianapolis, United StatesTaking people
  • Kidney Specialists of Southern NevadaLas Vegas, United StatesTaking people
  • Georgia NephrologyLawrenceville, United StatesTaking people
  • Academic Medical Research Institute (AMRI)Los Angeles, United StatesTaking people
  • Bioresearch PartnerMiami, United StatesTaking people
  • Renal AssociatesMontgomery, United StatesTaking people
  • NYU Medical CenterNew York, United StatesTaking people
  • CTR Oakwater, LLCOrlando, United StatesTaking people
  • St. Clair Nephrology ResearchRoseville, United StatesTaking people
  • Kaiser Permanente Sacramento Medical CenterSacramento, United StatesTaking people
  • Utah Kidney ResearchSalt Lake City, United StatesTaking people
  • DaVita Clinical Research San AntonioSan Antonio, United StatesTaking people
  • Northwest Louisiana Nephrology, LLC - ShreveportShreveport, United StatesTaking people
  • Carolina Nephrology, PASpartanburg, United StatesTaking people
  • Southwest Kidney Institute, PLC (SKI) - SurpriseSurprise, United StatesTaking people
  • Valiance Clinical Research - Internal MedicineTarzana, United StatesTaking people
  • Milwaukee Neprologists, SCWauwatosa, United StatesTaking people
  • Clinical Site Partners, LLC - OrlandoWinter Park, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the efficacy, safety, and tolerability of povetacicept in participants with primary membranous nephropathy (pMN).

The 3 groups in the trial

  • Phase 2b: PovetaciceptTreatment being tested

    Participants will be randomized to receive one of the two doses of Povetacicept.

    Treatment: Povetacicept

  • Phase 3: PovetaciceptTreatment being tested

    Participants will be randomized to receive one of the two doses of Povetacicept (dose selected based on Phase 2b).

    Treatment: Povetacicept

  • Phase 3: Calcineurin Inhibitor (CNI)Existing treatment, for comparison

    Participants will be randomized to receive the calcineurin inhibitor (CNI) Tacrolimus.

    Treatment: Tacrolimus

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase 2b/3 Adaptive, Randomized, Active-controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
Fit questions
Built from NCT07204275, who can take part
Record updated
30 October 2026